Research Site

Bad Berka 99437

2 studies enrolling now · 10 studies all time

What they study most

Anemia, Cancer, Chemotherapy-Induced Thrombocytopenia, Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer, Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV, Lung Cancer, Lung Neoplasms, NSCLC, Non-Small Cell Lung Cancer, Non-Small-Cell Lung Carcinoma, Non-Small-Cell Lung Carcinoma NSCLC, Non-small Cell Lung Cancer

Studies at this site

• A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) — Recruiting now
• A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC — Recruiting now
• Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC) — Running, not enrolling
• Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC — Running, not enrolling
• Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations — Running, not enrolling
• AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer — Completed
• Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy — Stopped early
• ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer — Completed
• ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures — Completed
• Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC) — Completed